Abstract
Purpose: To review the most important metabolic effects and clinical safety data of subthreshold micropulse diode laser (D-MPL) in diabetic macular edema (DME).
Methods: Review of the literature about the mechanisms of action and role of D-MPL in DME.
Results: The MPL treatment does not damage the retina and is selectively absorbed by the retinal pigment epithelium (RPE). MPL stimulates secretion of different protective cytokines by the RPE. No visible laser spots on the retina were noted on any fundus image modality in different studies, and there were no changes of the outer retina integrity. Mean central retinal sensitivity (RS) increased in subthreshold micropulse diode laser group compared to standard ETDRS photocoagulation group.
Conclusions: MPL is a new, promising treatment option in DME, with both infrared and yellow wavelengths using the less aggressive duty cycle (5%) and fixed power parameters. It appears to be safe from morphologic and functional point of view in mild center involving DME.
Keywords: Diabetic macular edema, diabetic retinopathy, fluorescein angiography, fundus autofluorescence, microperimetry, laser treatment, optical coherence tomography, subthreshold micropulse laser, retinal safety.
Current Medicinal Chemistry
Title:Subthreshold Laser Therapy for Diabetic Macular Edema: Metabolic and Safety Issues
Volume: 20 Issue: 26
Author(s): Stela Vujosevic, Ferdinando Martini, Enrica Convento, Evelyn Longhin, Olympia Kotsafti, Raffaele Parrozzani and Edoardo Midena
Affiliation:
Keywords: Diabetic macular edema, diabetic retinopathy, fluorescein angiography, fundus autofluorescence, microperimetry, laser treatment, optical coherence tomography, subthreshold micropulse laser, retinal safety.
Abstract: Purpose: To review the most important metabolic effects and clinical safety data of subthreshold micropulse diode laser (D-MPL) in diabetic macular edema (DME).
Methods: Review of the literature about the mechanisms of action and role of D-MPL in DME.
Results: The MPL treatment does not damage the retina and is selectively absorbed by the retinal pigment epithelium (RPE). MPL stimulates secretion of different protective cytokines by the RPE. No visible laser spots on the retina were noted on any fundus image modality in different studies, and there were no changes of the outer retina integrity. Mean central retinal sensitivity (RS) increased in subthreshold micropulse diode laser group compared to standard ETDRS photocoagulation group.
Conclusions: MPL is a new, promising treatment option in DME, with both infrared and yellow wavelengths using the less aggressive duty cycle (5%) and fixed power parameters. It appears to be safe from morphologic and functional point of view in mild center involving DME.
Export Options
About this article
Cite this article as:
Vujosevic Stela, Martini Ferdinando, Convento Enrica, Longhin Evelyn, Kotsafti Olympia, Parrozzani Raffaele and Midena Edoardo, Subthreshold Laser Therapy for Diabetic Macular Edema: Metabolic and Safety Issues, Current Medicinal Chemistry 2013; 20 (26) . https://dx.doi.org/10.2174/09298673113209990030
DOI https://dx.doi.org/10.2174/09298673113209990030 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Critical Questions for Preclinical Trials on Safety and Efficacy of Vascular Endothelial Growth Factor-Based Therapeutic Angiogenesis for Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Measurement and Mapping of Retinal Leakage and Retinal Thickness - Surrogate Outcomes for the Initial Stages of Diabetic Retinopathy
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Update on Pharmacologic Retinal Vascular Toxicity
Current Pharmaceutical Design Leukocytes in Diabetic Retinopathy
Current Diabetes Reviews Unusual Clinical Manifestations of the Antiphospholipid Syndrome
Current Rheumatology Reviews Ocular Complications of Drugs Used in Rheumatic Disease
Current Rheumatology Reviews Smoking and Eye Pathologies. A Systemic Review. Part II. Retina Diseases, Uveitis, Optic Neuropathies, Thyroid-Associated Orbitopathy
Current Pharmaceutical Design Vascular Endothelial Growth Factor and Angiopoietins in Neurovascular Regeneration and Protection Following Stroke
Current Neurovascular Research Recent Progress on Tumor Missile Therapy and Tumor Vascular Targeting Therapy as a New Approach
Current Vascular Pharmacology Subtypes of Antiphospholipid Antibodies in Neurologic Disorders: An Observational Study
Current Rheumatology Reviews The Involvement of Blood Coagulation Factor XIII in Fibrinolysis and Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Clinical Evidence of Intravitreal Triamcinolone Acetonide in the Management of Age-Related Macular Degeneration
Current Drug Targets Update on the Therapy of Behçets Disease
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Olive Oil and Haemostasis: Platelet Function, Thrombogenesis and Fibrinolysis
Current Pharmaceutical Design Drug Delivery to the Posterior Segment of the Eye: Challenges and Opportunities
Drug Delivery Letters Stroke in Women
Recent Patents on Cardiovascular Drug Discovery Intravitreal Anti-VEGF Drugs as Adjuvant Therapy in Diabetic Retinopathy Surgery
Current Diabetes Reviews Monitoring Calcific Aortic Valve Disease: The Role of Biomarkers
Current Medicinal Chemistry ANN Classification and Modified Otsu Labeling on Retinal Blood Vessels
Current Signal Transduction Therapy Hydroximic Acid Derivatives: Pleiotropic Hsp Co-Inducers Restoring Homeostasis and Robustness
Current Pharmaceutical Design